Break Through Digest |
A two year old child from Florida is free of signs of juvenile myelomonocytic leukemia (JMML), a very rare form of pediatric leukemia, seventeen months after receiving a transplant with cord blood from the National Cord Blood Program (NCBP) of the New York Blood Center’s Howard P. Milstein National Cord Blood Center.
Juvenile myelomonocytic leukemia generally affects children under the age of five and comprises less than one percent of infant leukemias. The prognosis for JMML is generally poor and most children with JMML die before reaching the age of three.
Adolfo Gonzalez was diagnosed with JMML when he was thirteen months old. “Adolfo Gonzalez would most likely not be alive today if it weren’t for the cord blood transplant,” said Gary Kleiner, M.D., Ph.D., pediatric immunologist at the University of Miami School of Medicine. “The mother who donated her cord blood to the public cord blood bank at New York’s National Cord Blood Program basically saved his life.”
Adolfo’s treatment included chemotherapy to destroy his leukemia cells followed by a cord blood stem cell transplant from NCBP. He did endure